[A22-09] Calcifediol (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2022
Project no.:
A22-09
Commission:
Commission awarded on 31.01.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease Stage 3 or 4 and vitamin D insufficiency or deficiency
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.